Global X China Biotech Innovation ETF (CHB)
- Previous Close
6.66 - Open
6.70 - Bid --
- Ask --
- Day's Range
6.64 - 6.70 - 52 Week Range
6.63 - 9.76 - Volume
154 - Avg. Volume
712 - Net Assets 1.41M
- NAV 6.72
- PE Ratio (TTM) 13.48
- Yield 0.58%
- YTD Daily Total Return -18.02%
- Beta (5Y Monthly) 0.66
- Expense Ratio (net) 0.65%
The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. It is non-diversified.
Global X Funds
Fund Family
China Region
Fund Category
1.41M
Net Assets
2020-09-22
Inception Date
Performance Overview: CHB
Trailing returns as of 2/21/2024. Category is China Region.
People Also Watch
Holdings: CHB
Top 10 Holdings (59.19% of Total Assets)
Sector Weightings
Recent News: CHB
Research Reports: CHB
Analyst Report: M.D.C. Holdings, Inc.
M.D.C. Holdings Inc., based in Denver, is a major homebuilder operating under the name Richmond American Homes. In 2023, total revenues were $4.5 billion. The average price of the 8,228 homes sold was $549,000, down 5% from 2022. The company's focus is on single-family detached homes. Roughly 58% of homebuilding revenues come from the West Coast, 28% from the Mountain states, and 14% from the East. The Financial Services segment consists of HomeAmerican Mortgage Corp., American Home Insurance Agency and American Home Title, which primarily provide services to Richmond American's home buyers. The company is on a calendar basis with the year ending on December 31.
RatingPrice TargetMHO: Raising target price to $142.00
M/I HOMES INC has an Investment Rating of HOLD; a target price of $142.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetNVR: Raising target price to $7,477.00
NVR INC has an Investment Rating of HOLD; a target price of $7477.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetNVR: Lowering target price to $7,285.00
NVR INC has an Investment Rating of HOLD; a target price of $7285.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target